EMPATHY
Project data
Project financing: 30 084 379,80 PLN (including financing for UMED: 1 024 068 PLN), financed by the Medical Research Agency (ABM) - ABM/2019/1
Project description:
The project includes a clinical trial which aims to test the effect of different SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) on clinical outcomes in acute heart failure (AHF). This study is highly significant because the data to date shows that SGLT-2 inhibitors in patients with type 2 diabetes reduce the risk of hospitalisation for heart failure and cardiovascular mortality, in addition, they reduced the risk of heart failure by 30% and resulted in a significant 35% relative risk reduction in hospitalisation for HF (heart failure), and SGLT-2 inhibitors reduced the primary composite endpoint including cardiovascular death and non-fatal myocardial infarction and stroke.
In contrast, no study has compared the effect of different SGLT-2 inhibitors on outcomes in AHF.
The project aims to assess:
- the effect of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical endpoints in patients with acute/uncompensated heart failure (AHF);
- the effect of SGLT-2 inhibitors on cardiac function;
- the effect of SGLT-2 inhibitors on biomarkers and circulating micro RNAs (miRNAs) and microbiome metabolites
- and propose a risk prediction scale to closely monitor the course of AHF and its treatment with SGLT-2 inhibitors based on selected miRNAs and biomarkers related to molecular pathways associated with disease progression.
Beneficiary
Consortium composed of:
- Medical University of Warsaw (WUM) – Leader
Partners:
- University Clinical Centre of Medical University of Warsaw
- Rev. Jerzy Popiełuszko Bielanski Hospital
- Medical University of Lodz
- Medical University of Gdańsk
- St John Paul II Independent Public Specialist Western Hospital
- Nicolaus Copernicus University of Toruń
- Hospital of Lord’s Transfiguration of Poznan University Of Medical Sciences (SKPP)
- Clinic of Interventional Cardiology, Institute of Cardiology, Jagiellonian University, Collegium Medicum, John Paul II Specialist Hospital in Krakow
- Medical University of Piastów Śląskich in Wrocław
- Medical University of Bialystok
- Medical University of Silesia in Katowice
- Medical University of Vienna
- Medical University of Graz
Coordinating Principal Investigator
prof. Jolanta Siller-Matula, MD, PhD
UMED Site Principal Investigator
prof. Robert Irzmański, MD, PhD